Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
Rhea-AI Summary
Reviva Pharmaceuticals (NASDAQ: RVPH) announced on March 18, 2026 that it intends to conduct a public offering of its common stock (or equivalents) and warrants. The offering is subject to market conditions and may not be completed.
The company said it plans to use net proceeds and existing cash to fund research and development, including the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital. A.G.P./Alliance Global Partners is the sole placement agent. The securities will be offered under an effective Form S-3 shelf registration declared effective February 13, 2024.
Positive
- Proceeds earmarked to fund RECOVER-2 Phase 3 trial
- Shelf registration effective Feb 13, 2024 enables offering
- Placement agent engaged: A.G.P./Alliance Global Partners appointed
Negative
- Offering introduces potential shareholder dilution
- Completion is uncertain; offering subject to market conditions
- Use of proceeds not quantified in the announcement
News Market Reaction – RVPH
On the day this news was published, RVPH declined 55.43%, reflecting a significant negative market reaction. Argus tracked a trough of -69.5% from its starting point during tracking. Our momentum scanner triggered 44 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $16M from the company's valuation, bringing the market cap to $13M at that time. Trading volume was exceptionally heavy at 8.2x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RVPH fell 9.73% while close biotech peers showed mixed moves, from -20.62% (LSB) to gains of 2.22–3.08% (NEUP, TENX, OKUR), pointing to a stock-specific reaction.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Sep 18 | Offering priced | Negative | -36.4% | Pricing of $9M public offering with large share and warrant package. |
| Sep 18 | Proposed offering | Negative | -36.4% | Announcement of proposed common stock and warrant offering for R&D funding. |
| Jun 26 | Offering priced | Negative | -53.1% | Pricing of $10M equity and warrant financing at $0.50 per share. |
| Jun 25 | Proposed offering | Negative | -53.1% | Proposed stock and warrant sale to fund R&D and working capital. |
| Dec 16 | Offering priced | Negative | -39.1% | Pricing of $18.0M stock and warrant deal at $1.50 per share. |
Equity offering announcements have consistently triggered large negative moves, often in the 30–50% range following both proposed and priced deals.
Over the past 18 months, Reviva has repeatedly used public offerings of common stock and warrants to fund R&D and corporate purposes, with A.G.P./Alliance Global Partners frequently acting as placement agent. Prior offerings in Dec 2024, Jun 2025, and Sep 2025 led to price drops between roughly 36–53% over the next day. Today’s proposed offering, also combining equity and warrants for schizophrenia programs, fits this pattern of financing-driven dilution pressure.
Historical Comparison
Past offering headlines for RVPH saw an average move of about -43.65%. Today’s -9.73% decline is milder but consistent with the stock’s historically negative reaction to dilution events.
Since late 2024, RVPH has executed multiple equity-and-warrant financings, repeatedly using public offerings to support R&D and corporate needs, establishing a clear pattern of dilution-driven capital raising.
Market Pulse Summary
The stock dropped -55.4% in the session following this news. A negative reaction despite the familiar use-of-proceeds language fits RVPH’s pattern around equity raises, where prior offerings averaged about -43.65% the next day. The proposed sale of common stock and warrants adds to an extensive history of dilution used to fund brilaroxazine development. Combined with previously disclosed going‑concern risks and capital‑structure flexibility, this financing overhang has often pressured the share price.
Key Terms
warrants financial
placement agent financial
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
The Company currently intends to use the net proceeds from the offering together with its existing cash and cash equivalents to fund research and development activities, including its planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital and other general corporate purposes.
The securities will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276848), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2024, and declared effective by the SEC on February 13, 2024. A preliminary prospectus supplement will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus, when available, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering and uncertainties related to the size, timing, completion, and use of proceeds from the proposed offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2024 and Forms 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
REVIVA CONTACTS:
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
What is Reviva Pharmaceuticals (RVPH) announcing on March 18, 2026?
How will the RVPH offering proceeds be used?
Who is the placement agent for Reviva's RVPH offering?
Is the RVPH offering already registered with the SEC?
What are the risks to RVPH shareholders from this offering?
